VivoSim Labs, Inc. (VIVS) - Comprehensive Stock & Company Analysis
One-Sentence Summary of Key Findings: VivoSim Labs (VIVS), a microcap biotechnology services company (formerly Organovo Holdings) specializing in 3D human tissue models for non-animal drug toxicology testing, shows early commercial traction via a $5M Eli Lilly milestone and China sales but faces severe financial losses, minimal analyst coverage, and high volatility typical of penny stocks.
Stock Performance and Company Financials
Stock Performance Overview
- Fact: The stock has exhibited extreme volatility with significant trading volume spikes associated with news releases (e.g., partnerships and financings). Yahoo Finance Historical Data
- Fact: YTD and 1-year returns have been positive amid broader market gains, though multi-year performance reflects the challenges of a small-cap biotech. Yahoo Finance Performance
- Interpretation: News-driven momentum (e.g., Lilly payment, China entry) appears to drive short-term price movements more than fundamentals.
- Uncertainty: Long-term trajectory remains highly uncertain due to the company's early-stage commercial status and dependence on milestone payments.
Data Limitation: Exact historical price charts and volume data are dynamic; refer to source links for latest charts. No reverse split or other adjustments are detailed in summaries.
Company Financials (TTM / Recent Periods)
| Metric |
Value |
Notes / Source |
| Revenue (TTM) |
$131,000 |
Primarily from services; very low base. Yahoo Finance |
| Net Income (TTM) |
-$13.84 million |
Ongoing operating losses typical of development-stage biotech. Yahoo Finance |
| EPS (TTM) |
-$5.35 |
Diluted EPS reflects share count and losses. Yahoo Finance |
| Cash Position (MRQ) |
~$5.02 million |
bolstered by recent private placements. Yahoo Finance |
| Market Cap |
~$1.2M - $1.7M range (recent estimates) |
Microcap status. Simply Wall St |
| Employees |
9–15 |
Small team; reports vary slightly by date. Yahoo Finance Profile |
Recent Financial & Operational Highlights (Bullets)
- Fact: Received $5M milestone payment from Eli Lilly; company guidance projects >500% revenue growth in FY2027 (company-provided outlook). GlobeNewswire (Jul 2026)
- Fact: Completed $4M private placement with healthcare-focused institutional investor. GlobeNewswire (Jul 2026)
- Fact: First commercial sales of NAMkind™ services in China; expanded Asia-Pacific distribution. GlobeNewswire (Jul 2026)
- Interpretation: These events signal potential commercialization progress in the non-animal testing (NAM) space, aligned with FDA encouragement of human-relevant methods.
- Uncertainty / Limitation: Revenue remains minimal; sustained profitability is not yet demonstrated. Historical Organovo data may not directly compare post-rebrand. Fiscal year ends March 31.
More Information: Yahoo Finance Financials | Company Website
Analyst Ratings
- Fact: Extremely limited Wall Street coverage — only 1 analyst rating in the last 12 months, resulting in a consensus "Sell" rating. MarketBeat
- Uncertainty: Some sources reference an average price target of $64.80; this appears inconsistent with the current microcap valuation and may stem from pre-rebrand/ pre-split data or limited/no recent updates — treat with high caution. Barron's
- Interpretation: Lack of broad analyst interest reflects the company's small size, early commercial stage, and high risk profile.
| Source |
Consensus |
# Analysts |
Notes |
| MarketBeat |
Sell |
1 |
Based on last 12 months |
| Other (e.g., Barron's, WSJ) |
Sell / Limited |
1 |
Target figures flagged as potentially outdated |
Data Limitation: No earnings estimates or growth projections available from multiple analysts on Yahoo Finance or similar platforms. Ratings can change rapidly for microcaps.
More Information: Yahoo Finance Analysis | MarketBeat Forecast
Customers and Competitors
Customers
- Fact: Eli Lilly — received $5M milestone payment for services (likely toxicology/efficacy testing). GlobeNewswire (Jul 2026)
- Fact: Pharmaceutical and biotechnology companies at various drug development stages (liver/intestine toxicity screening and bespoke services). Yahoo Finance Profile
- Fact: Initial commercial customers in China via direct sales and distribution partners in Korea/China/Asia-Pacific. GlobeNewswire
- Interpretation: Focus on big pharma and emerging biotechs seeking alternatives to animal testing.
Competitors
| Company |
Focus / Relation |
Notes |
| Emulate, Inc. (private) |
Organ-on-a-chip / human tissue models |
Direct competitor in NAM/3D tissue testing space. |
| Other 3D bioprinting / NAM firms |
Various organ models |
Limited public peers; broader competition from traditional CROs and animal testing providers. |
| Historical: Organovo (pre-rebrand) |
Same company / technology platform |
VIVS is the continuation of Organovo Holdings' 3D bioprinting efforts. |
Interpretation: VivoSim positions itself as superior in liver tox prediction per company presentations; competitive landscape is niche and evolving with regulatory shifts toward non-animal methods.
More Information: Company Site (NAMkind details) | Search "NAM liver toxicology competitors" for industry reports.
Company Overview & History
- Fact: Provides 3D human tissue models (liver, intestine) for drug candidate testing using proprietary bioprinting and organoid technologies; emphasizes New Approach Methodologies (NAM) to reduce/replace animal testing. Yahoo Finance
- Fact: Incorporated 2007; headquartered in San Diego, CA; rebranded from Organovo Holdings, Inc. to VivoSim Labs, Inc. in April 2025. Yahoo Finance
- Fact: ~9-15 employees; develops high-throughput, bioprinted, flow/stretch capable 3D systems. Yahoo Finance Profile
- Interpretation: Rebrand and pivot emphasis align with 2025 FDA signals favoring human-relevant testing methods.
More Information: Official Website | Yahoo Profile
Recent News Highlights
- Jul 2026: $5M Lilly milestone + FY2027 growth guidance. GlobeNewswire
- Jul 2026: China commercial sales launch. GlobeNewswire
- Jul 2026: $4M private placement. GlobeNewswire
- Ongoing: Nasdaq compliance updates and presentations on ADC/liver tox data superiority. Yahoo News
Overall Data Limitations & Assumptions: Information compiled from public sources as of August 2026; financials are TTM or FY-end March 31 and subject to updates in SEC filings. Microcap stocks have sparse coverage and high execution risk. Analyst data is minimal and potentially stale. Always verify with primary sources (SEC EDGAR, company IR) and consult professionals. No investment advice implied.